Natco Q2 FY27: PAT down 61% YoY to ₹203 Cr (consolidated) as Lenalidomide fades
PAT -60.88% YoY · revenue -29.03% · margins compressing
₹967.3 Cr
-29.03% YoY
₹202.6 Cr
-60.88% YoY
19.87%
-15.5pp YoY
₹11.31
Natco Pharma's consolidated profit for Q2 FY27 came in at ₹202.6 Cr, down 60.9% year-on-year from ₹517.9 Cr and essentially flat quarter-on-quarter (-1.9% versus ₹206.5 Cr). Consolidated revenue from operations of ₹967.3 Cr fell 29.0% YoY but rose 31.6% QoQ. The YoY comparison is the one that matters here: Q2 FY26 was inflated by an exclusivity-driven Lenalidomide (generic Revlimid) spike in the US that has since normalised, and management's own press release attributes the YoY decline "largely" to lower Lenalidomide revenue, partly offset by growth in the base business and subsidiaries. International Formulations revenue (including subsidiaries) nearly halved YoY to ₹668.4 Cr from ₹1,140.2 Cr, even as it rose from ₹477.1 Cr in Q1 FY27 — the QoQ pickup looks like a stabilising base business, not a reversal of the structural Lenalidomide decline.
Q2 FY-2027 vs prior quarters
Margins compressed on both comparisons: EBITDA margin before share of associate fell to 30.4% from 46.4% a year ago (roughly flat versus 30.9% in Q1), and net margin on total income slid to about 19.9% from 35.4% YoY and 26.0% QoQ. The sequential margin stability, alongside a 31.6% QoQ revenue recovery, suggests the base pharmaceuticals and agrochemical businesses are no longer deteriorating quarter-on-quarter even as the YoY base effect from Lenalidomide persists. ₹29.2 Cr of the consolidated PAT came from NATCO's 49%-owned associate Adcock Ingram Holdings (South Africa, revenue ₹1,343.8 Cr, PAT ₹80.5 Cr for the quarter) — down from an unusually large ₹84.3 Cr associate contribution in Q1 that reflected provisional purchase-price-accounting adjustments after the stake increase; this makes the QoQ PAT comparison a little noisier than the headline flat print suggests. Standalone PAT of ₹143.2 Cr was down a sharper 71.4% YoY (versus consolidated's 60.9%), a double-digit-point divergence from the consolidated story driven mainly by the associate profit share and subsidiary earnings that sit outside the standalone entity — both numbers will circulate, and the gap is explained by consolidation scope, not a data error.
The stock went into the print at ₹782.45, down 0% over the past month of trading.
FY27: Revenue 3,400-3,500 Cr (but Q1 at 735 Cr annualizes to ~2,940 Cr); PAT 700-750 Cr (maintained despite Q1 weakness). Capex ~250-300 Cr/year ongoing.
— This quarter: missed
Against management's own FY27 guidance (revenue ₹3,400-3,500 Cr, PAT ₹700-750 Cr, given on the Q1 call under a cautious, high-risk tone), H1 FY27 revenue from operations of ₹1,702.5 Cr annualises to roughly ₹3,405 Cr — inside the guided band, a genuine improvement on the ~₹2,940 Cr pace flagged after Q1's weak start. PAT is murkier: H1 profit before the associate's share was ₹295.6 Cr, annualising to ~₹591 Cr, below the ₹700-750 Cr guided range; only once the outsized Q1 associate contribution is folded in does the H1 total of ₹409.1 Cr annualise above guidance (~₹818 Cr), a result that leans on a provisional, acquisition-related accounting item rather than recurring operations. On balance this reads as tracking below the PAT guidance on a core basis. We found no quarter-specific Street consensus for this print to grade against (vsStreet unknown); a web search surfaced only a full-year FY27 analyst estimate materially below even management's own guidance, underscoring that the market has been pricing a tougher outcome than the company's stated band. The quarter's corporate actions — a completed ₹1,279 Cr rights issue (1.7 Cr shares at ₹750 each) and a second interim dividend of ₹1.25/share declared alongside results — both land after the Lenalidomide-driven profit base has already reset lower, and tie to funding the expanded Adcock Ingram stake and the company's ongoing ₹250-300 Cr/year capex plan.
W1
Management has said Q2 FY27 was the last meaningful quarter for Lenalidomide, with Q3/Q4 contributions expected to be negligible — watch whether the base business can hold the ~₹967 Cr quarterly revenue run-rate without it.
W2
FY27 guidance of ₹700-750 Cr PAT implies H2 must deliver well above the ~₹591 Cr annualised core (ex-associate) run-rate seen in H1 — watch Q3 PAT for signs of a step-up.
W3
Adcock Ingram associate stake now at 49% with provisional PPA still being finalised — watch for the PPA to be trued up and the associate's profit contribution to normalise from Q1's elevated ₹84.3 Cr.
Figures converted from ₹ in millions (÷10). Consolidated PAT (₹202.6 Cr) = PBT−tax (₹173.4 Cr) + ₹29.2 Cr share of profit of associate Adcock Ingram (stake raised to 49% this quarter, provisional PPA); standalone arithmetic ties exactly. Prior-quarter/year-ago revenue, PAT and EPS all cross-checked to the exact decimal against the company's own comparative columns.
Informational and educational content only. Not investment advice.